GSK GlaxoSmithKline
- 34.090
- +0.130+0.38%
- 34.260
- +0.170+0.50%
GlaxoSmithKline News
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
GSK, Pfizer RSV Shots to Get Warning of Rare Neurological Disorder
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
GSK's Bone Cancer Treatment Receives Breakthrough Designation From US FDA
GSK's Experimental Cancer Drug Wins Receives Support From US Regulator | LSE:GSK, NYSE:GSK
Bernstein Remains a Buy on GlaxoSmithKline (GSK)
Bird Flu Claims First U.S. Life in Louisiana
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Why Is GSK Plc (NYSE:GSK) Among the Best FTSE Dividend Stocks to Buy Now?
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
GSK Gets Approval in China for Nucala for Rhinosinusitis
GSK Wins Chinese Nod for Nucala as Chronic Rhinosinusitis Treatment
GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.
Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.
GlaxoSmithKline (GSK.US) has submitted for the market approval of its ultra-long-acting IL-5 monoclonal antibody in China.
The CDE website shows that GlaxoSmithKline (GSK.US) has applied for the market launch of depemokimab in the country.
No Data
